Did Aphria Inc (TSX:APHA) Convincingly Address Short-Seller Claims?

Is Aphria Inc’s (TSX:APHA)(NYSE:APHA) rebutal of short seller claims enough to restore confidence in the stock?

| More on:
Man making notes on graphs and charts

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

In the face of a scathing short seller report that violently shook the marijuana stock in December last year, Aphria Inc (TSX:APHA)(NYSE:APHA) urgently set up a committee of independent company directors to review troublesome Latin American acquisition transactions.

Short sellers Quintessential Capital Management and Hindenburg Research claimed that Aphria insiders unethically created shell companies that bought “largely worthless” cannabis assets in Argentina, Colombia and Jamaica and quickly sold the same assets to the company’s shareholders at exorbitant prices for hefty personal gains.

Some overwhelming “incriminating evidence” of the purported misdeeds was then provided in the short seller report; the market had no option but to panic sell the stock. The company’s board did well to announce an independent inquiry into the allegations, and hired well-respected professional teams in December to look into the matter.

There was even some suggestion that some of the purchased assets could be fictional, as the short sellers’ researcher could not locate a farm.

Paid prices were acceptable, but…

On February 15, Aphria reported on the independent committee’s findings, and much to the investing public’s relief, the acquired Latin American assets were confirmed to be in place, licenses have been verified, and development is taking place just as the company had previously announced.

Most noteworthy, the consideration paid for these assets was “within an acceptable range” when compared to similar transactions by competitors, “be it near the top of the range of observable valuation metrics.”

The fact that comparable competitor transactions in Latin America had valuation multiples close to Aphria’s is reassuring indeed, and the idea that the assets are present, growing and actually “worth” something calms a lot of nerves.

However, the qualification that the consideration was near the top of observable valuation metrics is a slight setback, especially given that the company’s acceptance of poor internal disclosure and the presence of conflicts of interests among some company directors. These findings could give some merit to the recently filed investor class action lawsuits.

The resignation of three key company insiders during the inquiry period seems like an internal corporate disciplinary action.

Did Aphria adequately refute short seller claims?

The company’s board has done well in carrying out a thorough review of Latin American transactions, and the wording in the report seems carefully crafted to avoid further hurting the stock price.

Instead of directly commenting on accusations that insiders unethically created shell companies to front-run common shareholders, the company commented on general corporate governance deficiencies instead and stated some recommendations for corporate governance enhancements.

It appears that the independent board is keen on preserving shareholder trust and confidence in the company, and publicly condemning senior executives, or suing them like what recently happened at Namaste Technologies. Namaste decided to fire its CEO and sue him for damages at the same time, causing a massive selloff on its shares, which was not the most ideal route.

The special committee isn’t necessarily refuting short seller allegations of insider shenanigans to line their pockets; it’s only arguing that the considerations paid by Aphria were somewhat in line with comparable competitor transactions, and the company will improve its corporate governance practices and disclosure policies to better manage conflicts of interests.

Further, the company will also confirm the independence and qualifications of external advisors prior to engagement on transactional matters. This appears to confirm that the advisors used in the Latin American deals were conflicted too, just like the short sellers claimed.

Foolish bottom line

One could conclude that Aphria has softly acknowledged the existence of problems in its Latin American deals. The company slightly overpaid for acquired assets, but not enough to warrant a write-down of the assets’ carrying values as the consideration was “acceptable.”

The company is working on repairing its corporate governance reputation, and I applauded its earlier decision to improve the profile. Adopting strong ethics codes and guidelines like the those of highly regarded CFA Institute could help tackle the ethical dilemmas that many small marijuana firms face as they undergo an industry consolidation phase, and this could preserve the investing public’s hard-earned trust in the nascent industry.

The fact that the company’s flagship production facility is current Good Manufacturing Practices (cGMP) certified makes me less concerned about claims of low product quality at Limington, and the company’s use of independent board members, independent legal advisors, independent forensic advisors, and independent financial advisors in attempting to debunk short seller claims gave enough credibility to the report.

Investors will like that very much.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Investing

money cash dividends
Dividend Stocks

2 Passive-Income ETFs to Buy in 2022

Unlike stocks, distribution-focused ETFs may not offer an equally healthy capital-appreciation potential, but they might still be worth buying.

Read more »

Businessperson's Hand Putting Coin In Piggybank
Dividend Stocks

RRSP Investors: 2 Top Total-Return Stocks to Build Retirement Wealth

These top TSX dividend stocks offer high yields and currently trade at discounted prices.

Read more »

Dollar symbol and Canadian flag on keyboard
Dividend Stocks

The 3 Best TSX Dividend Stocks That Pay Cash Monthly

Looking to earn monthly passive income from top dividend stocks? Here are three fresh ideas for July 2022.

Read more »

Cogs turning against each other
Dividend Stocks

2 Resilient Value Stocks That Could Weather the Storm

The resilient businesses of two value stocks can help you endure recessionary pressures and deliver superior returns in 2022.

Read more »

exchange traded funds
Investing

3 Must-Buy Bank of Montreal ETFs to Ride Out a Recession

Passive investors may wish to buy BMO Covered Call Canadian Banks ETF (TSX:ZWB) and two other incredible ETFs that right…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

Retirees: Fortify Your Portfolio by Building a 2nd Pension

One of the best ways to utilize your retirement savings without depleting them is to invest them in dividend stocks.…

Read more »

Man holding magnifying glass over a document
Stocks for Beginners

The Valuation Conundrum: P/E Ratio vs. P/S Ratio

Did you buy a stock with low P/S ratio and make a loss? Most investors fall prey to the valuation…

Read more »

growing plant shoots on stacked coins
Energy Stocks

Buy the Dip? 2 TSX Energy Stocks With Fast-Growing Dividends

TSX energy stocks have seen a double-digit decline in June. Here are two stocks with incredibly fast-growing dividends to consider…

Read more »